May 14 (Reuters) - Enliven Therapeutics Inc ELVN.O:
ENLIVEN THERAPEUTICS ANNOUNCES UPDATED POSITIVE DATA FROM PHASE 1 CLINICAL TRIAL OF ELVN-001 IN CML AND ORAL PRESENTATION AT THE EHA 2025 CONGRESS
ENLIVEN THERAPEUTICS INC - ELVN-001 SHOWS FAVORABLE SAFETY AND TOLERABILITY PROFILE
Source text: ID:nPn7pwJnCa
Further company coverage: ELVN.O
(((( Reuters.Briefs@thomsonreuters.com ;));))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.